Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Classifying the antibody-negative NMO syndromes: Clinical, imaging, and metabolomic modeling.

Yeo T, Probert F, Jurynczyk M, Sealey M, Cavey A, Claridge TDW, Woodhall M, Waters P, Leite MI, Anthony DC, Palace J.

Neurol Neuroimmunol Neuroinflamm. 2019 Oct 28;6(6):e626. doi: 10.1212/NXI.0000000000000626. Print 2019 Nov.

2.

A randomised double-blind placebo-controlled feasibility trial of flavonoid-rich cocoa for fatigue in people with relapsing and remitting multiple sclerosis.

Coe S, Cossington J, Collett J, Soundy A, Izadi H, Ovington M, Durkin L, Kirsten M, Clegg M, Cavey A, Wade DT, Palace J, DeLuca GC, Chapman K, Harrison JM, Buckingham E, Dawes H.

J Neurol Neurosurg Psychiatry. 2019 May;90(5):507-513. doi: 10.1136/jnnp-2018-319496. Epub 2019 Mar 4.

PMID:
30833449
3.

A protocol for a randomised double-blind placebo-controlled feasibility study to determine whether the daily consumption of flavonoid-rich pure cocoa has the potential to reduce fatigue in people with relapsing and remitting multiple sclerosis (RRMS).

Coe S, Collett J, Izadi H, Wade DT, Clegg M, Harrison JM, Buckingham E, Cavey A, DeLuca GC, Palace J, Dawes H.

Pilot Feasibility Stud. 2018 Jan 23;4:35. doi: 10.1186/s40814-018-0230-7. eCollection 2018.

4.

Metabolomics reveals distinct, antibody-independent, molecular signatures of MS, AQP4-antibody and MOG-antibody disease.

Jurynczyk M, Probert F, Yeo T, Tackley G, Claridge TDW, Cavey A, Woodhall MR, Arora S, Winkler T, Schiffer E, Vincent A, DeLuca G, Sibson NR, Isabel Leite M, Waters P, Anthony DC, Palace J.

Acta Neuropathol Commun. 2017 Dec 6;5(1):95. doi: 10.1186/s40478-017-0495-8.

5.

Time- and Region-Specific Season of Birth Effects in Multiple Sclerosis in the United Kingdom.

Rodríguez Cruz PM, Matthews L, Boggild M, Cavey A, Constantinescu CS, Evangelou N, Giovannoni G, Gray O, Hawkins S, Nicholas R, Oppenheimer M, Robertson N, Zajicek J, Rothwell PM, Palace J.

JAMA Neurol. 2016 Aug 1;73(8):954-60. doi: 10.1001/jamaneurol.2016.1463.

PMID:
27366989
6.

Nurse led telephone assessment of expanded disability status scale assessment in MS patients at high levels of disability.

Huda S, Cavey A, Izat A, Mattison P, Boggild M, Palace J.

J Neurol Sci. 2016 Mar 15;362:66-8. doi: 10.1016/j.jns.2016.01.011. Epub 2016 Jan 6.

PMID:
26944120
7.

Multiple sclerosis in Japan appears to be a milder disease compared to the UK.

Piccolo L, Kumar G, Nakashima I, Misu T, Kong Y, Wakerley B, Ryan S, Cavey A, Fujihara K, Palace J.

J Neurol. 2015;262(4):831-6. doi: 10.1007/s00415-015-7637-3. Epub 2015 Jan 22.

PMID:
25605435
8.

A type 2 biomarker separates relapsing-remitting from secondary progressive multiple sclerosis.

Dickens AM, Larkin JR, Griffin JL, Cavey A, Matthews L, Turner MR, Wilcock GK, Davis BG, Claridge TD, Palace J, Anthony DC, Sibson NR.

Neurology. 2014 Oct 21;83(17):1492-9. doi: 10.1212/WNL.0000000000000905. Epub 2014 Sep 24.

9.

Targeting ASIC1 in primary progressive multiple sclerosis: evidence of neuroprotection with amiloride.

Arun T, Tomassini V, Sbardella E, de Ruiter MB, Matthews L, Leite MI, Gelineau-Morel R, Cavey A, Vergo S, Craner M, Fugger L, Rovira A, Jenkinson M, Palace J.

Brain. 2013 Jan;136(Pt 1):106-15. doi: 10.1093/brain/aws325.

PMID:
23365093
10.

Comparability of tympanic and oral mercury thermometers at high ambient temperatures.

Chue AL, Moore RL, Cavey A, Ashley EA, Stepniewska K, Nosten F, McGready R.

BMC Res Notes. 2012 Jul 16;5:356. doi: 10.1186/1756-0500-5-356.

11.

Hydration and independence in activities of daily living in people with multiple sclerosis: a pilot investigation.

Collett J, Dawes H, Cavey A, Meaney A, Sackley C, Wade D, Howells K.

Disabil Rehabil. 2011;33(19-20):1822-5. doi: 10.3109/09638288.2010.549286. Epub 2011 Jan 13.

PMID:
21231820
12.

Autoantibodies to glutamic acid decarboxylase in patients with epilepsy are associated with low cortical GABA levels.

Stagg CJ, Lang B, Best JG, McKnight K, Cavey A, Johansen-Berg H, Vincent A, Palace J.

Epilepsia. 2010 Sep;51(9):1898-901. doi: 10.1111/j.1528-1167.2010.02644.x.

13.

Mississippi's infectious disease hotline: a surveillance and education model for future disasters.

Cavey AM, Spector JM, Ehrhardt D, Kittle T, McNeill M, Greenough PG, Kirsch TD.

Prehosp Disaster Med. 2009 Jan-Feb;24(1):11-7.

PMID:
19557953
14.

Serum antibodies in epilepsy and seizure-associated disorders.

McKnight K, Jiang Y, Hart Y, Cavey A, Wroe S, Blank M, Shoenfeld Y, Vincent A, Palace J, Lang B.

Neurology. 2005 Dec 13;65(11):1730-6.

PMID:
16344514

Supplemental Content

Support Center